...
首页> 外文期刊>Journal of Medicinal Chemistry >Pentafluorosulfanyl-Substituted Benzopyran Analogues As New Cyclooxygenase-2 Inhibitors with Excellent Pharmacokinetics and Efficacy in Blocking Inflammation
【24h】

Pentafluorosulfanyl-Substituted Benzopyran Analogues As New Cyclooxygenase-2 Inhibitors with Excellent Pharmacokinetics and Efficacy in Blocking Inflammation

机译:五氟磺酰基取代的苯并吡喃类似物作为新的环氧化酶-2抑制剂,具有优异的药代动力学和抗炎症的功效

获取原文
获取原文并翻译 | 示例

摘要

In this report, we disclose the design and synthesis of a series of pentafluorosulfanyl (SF5) benzopyran derivatives as novel COX-2 inhibitors with improved pharmacokinetic and pharmacodynamic properties. The pentafluorosulfanyl compounds showed both potency and selectivity for COX-2 and demonstrated efficacy in several murine models of inflammation and pain. More interestingly, one of the compounds, R,S-3a, revealed exceptional efficacy in the adjuvant induced arthritis (ATA) model, achieving an ED50 as low as 0.094 mg/kg. In addition, the pharmacokinetics of compound R,S-3a in rat revealed a half-life in excess of 12 h and plasma drug concentrations well above its IC90 for up to 40 h. When R,S-3a was dosed just two times a week,in the AIA model, efficacy was still maintained. Overall, drug R,S-3a and other analogues are suitable candidates that merit further investigation for the treatment of inflammation and pain as well as other diseases where COX-2 and PGE(2) play a role in their etiology.
机译:在本报告中,我们公开了苯并吡喃衍生物是新颖的COX-2抑制剂具有改善的药代动力学和药效学性质的设计和一系列五氟硫烷基(SF 5)的合成。所述五氟硫烷基化合物显示在炎症和疼痛的几个小鼠模型对COX-2两者的效力和选择性并表现出功效。更有趣的是,化合物中,R,S-3a的一个,揭示了在佐剂诱导的关节炎(ATA)模型特殊的功效,实现的ED 50低达0.094毫克/公斤。此外,化合物R的药代动力学,S-3A在大鼠显示大大高于其IC90长达40小时超过12种小时,血浆药物浓度的半衰期。当R,S-3a以给药一周只是两次,在AIA模型中,功效仍然保持。总的来说,药物R,S-3a和其它类似物是值得用于治疗炎症进一步调查和疼痛,以及其他疾病,其中COX-2和PGE(2)在它们的病因学中发挥作用的合适候选者。

著录项

  • 来源
    《Journal of Medicinal Chemistry 》 |2017年第10期| 共12页
  • 作者单位

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Guangzhou Inst Biomed &

    Hlth Drug Discovery Pipeline 190 Kaiyuan Ave Guangzhou 510530 Guangdong Peoples R China;

    Euclises Pharmaceut St Louis MO 63108 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学 ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号